Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors

Exclusion Criteria

• •1\. Patients with resectable pancreatic adenocarcinoma without risk factors.
• •2\. Patients with borderline pancreatic adenocarcinoma.
• •3\. Patients with locally advanced pancreatic adenocarcinoma.
• •4\. Patients with metastatic adenocarcinoma of the pancreas.
• •5\. Patients who have received prior chemotherapy or radiotherapy for pancreatic adenocarcinoma
• •6\. Pathological subtypes other than adenocarcinoma.
• •7\. Patients included in a clinical trial in a period of 6 months prior to inclusion in this study.
• •8\. A past history of allergic reaction attributed to 5-FU, leucovorin, Irinotecan or Oxaliplatin or to compounds of similar chemical or biological composition.
• •9\. Uncontrolled breakthrough disease.
• •10\. Patients with HIV, HBV and HCV positive and currently under antiretroviral therapy.
• •11\. Other active malignancies
• •12\. Pre-existing neuropathy, grade \> 1.
• •13\. Inflammatory bowel disease that is not controlled, or under current active therapy.